Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential of the company in Austria and her aspirations as a young, ambitious leader.
You have been working at AstraZeneca for many years in a variety of different roles. What attracted you to the Austrian country president position?
"Despite constraints faced by the industry through reimbursement reforms that have recently been put in place, Austria enhances innovation by giving companies opportunities for early launches."
